OCUGEN, INC. Marketable Securities, Realized Loss, Other than Temporary Impairments, Amount (Deprecated 2018-01-31)
OCUGEN, INC. (OCGN) reported Marketable Securities, Realized Loss, Other than Temporary Impairments, Amount (Deprecated 2018-01-31) of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount · last filed 2018-03-15
- OCUGEN, INC. marketable securities, realized loss, other than temporary impairments, amount (deprecated 2018-01-31) for fiscal 2017 was $0.00.
| Period end | Marketable Securities, Realized Loss, Other than Temporary Impairments, Amount (Deprecated 2018-01-31) 12 month |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |